Description
Danoprevir is a NS3/4A protease inhibitor. The hepatitis C viral replication is thought to relate to the HCV NS3/4A protease, the inhibition of which is a target of drug development. Danoprevir may be effective against COVID-19.
Danoprevir
Product ID D017538
Cas No. 850876-88-9
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 850876-88-9 |
|---|---|
| Purity | ≥98% |
| Formula | C35H46FN5O9S |
| Formula Wt. | 731.83 |
| Chemical Name | (2R,6S,12Z,13aS,14aR,16aS)-14a-[(Cyclopropylsulfonyl)carbamoyl]-6-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1, 2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-1,3-dihydro-2H-isoindole-2-carboxylate |
| IUPAC Name | (2R,6S,12Z,13aS,14aR,16aS)-14a-[(Cyclopropylsulfonyl)carbamoyl]-6-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1, 2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-1,3-dihydro-2H-isoindole-2-carboxylate |
| Synonym | lopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate, ITMN-191, RO5190591, RG 7227 |
Shipping and Storage
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Miao M, Jing X, Clercq E, et al. Danoprevir for the treatment of hepatitis C virus infection: design, development, and place in therapy. Drug Des Devel Ther. 2020 Jul 14;14:2759-2774. PMID: 32764876.
Chen H, Zhang Z, Wang L, et al. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. Medicine (Baltimore). 2020 Nov 25;99(48):e23357. PMID: 33235105.